[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版).临床肝胆病杂志,2018,34:947-957. [2] Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol, 2019,71:793-801. [3] 王锐,陈文婷.老年与青年非酒精性脂肪肝病患者临床特点比较.中国老年学杂志,2017,37:922-923. [4] 魏雅楠,邓利华,王晶桐.老年非酒精性脂肪性肝病患者纤维化评分与颈动脉不稳定斑块的相关性研究.中华老年医学杂志,2019,38:1251-1253. [5] 陈佳良,段绍杰,陈洁, 等.非酒精性脂肪性肝病血清无创诊断模型研究进展.医学综述,2019,25:2940-2948. [6] Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018,15:11-20. [7] 杨霞虹,刘涛.血清miRNA-21在炎症性疾病中的应用.中华临床免疫和变态反应杂志,2020,14:71-75. [8] 郎立敏,陈妍.线粒体能量代谢相关miRNA的研究进展.中国生物制品学杂志,2019,32:703-706. [9] 黄翀,郑雅慧,张巨波.基于GEO数据库芯片探索miRNA参与肝纤维化的潜在机制.肝脏,2019,24:1381-1386. [10] Guo Y, Xiong Y, Sheng Q, Zhao S, Wattacheril J, Flynn CR. A micro-RNA expression signature for human NAFLD progression. J Gastroenterol, 2016,51:1022-1030. [11] Hanin G, Yayon N, Tzur Y, et al. miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression. Gut, 2018,67:1124-1134. [12] Shao S, Yao Z, Lu J, et al. Ablation of prolactin receptor increases hepatic triglyceride accumulation. Biochem Biophys Res Commun, 2018,498:693-699. |